Svas Biosana S.p.a. · MIL:SVS
Svas Biosana — Non-Deal Roadshow (October 2026)
16 slides from Svas Biosana's roadshow presentation, October 2026
Slide 1: Investor Presentation October 2026
Investor Presentation October 2026 REVERSE ROADSHOW BANCA PROFILO 2026
Slide 2: Shareholders' Structure & Geographical Presence
Shareholders’ Structure & Geographical Presence Shareholders (1) Geographical Presence Free Float and 21 Monte Others Somma S.r.l. 29,08% 43,86% (2) SVAS Biosana S.p.A. 6,93% Agrinvest S.r.l. 0,93% (3) Belforte S.r.l. 5,46% (3) Cofi Italia S.r.l. Umberto Perillo 8,19% (3) 5,56% (1) Updated to June 1
Slide 3: Group Overview
Group Overview SVAS Biosana Group (“SVAS”, the “Company” or the “Group”) is an Italian leading player in the medical devices and disposables sector, acting Svas Biosana «At a Glance» both as a manufacturer and as a distributor. Key Financial Highlights The Group was founded in Southern Italy in 1972
Slide 4: Group Overview: Geographical Presence and History
Group Overview Geographical Presence and History Warehouses and Offices ▪ Somma Vesuviana (NA) – 12.200 sqm: Chemical Microbiologic Division Division ❑ Site 1 (Via Trentola 7) Medical Devices in development Cosmetics Pharmaceutical ❑ Site 2 (Via Colle 104) Expertise Micro & Nanotechnology Bioenginee
Slide 5: Group Overview: Business Snapshot
Production & Group Overview Legend Sale Distribution & Business Snapshot Sale Company Activity Production Distribution Business €15,9m €5,1m €11,9m Mark €25,3m €12,2m Farmex Medical Svas Bormia Line(1) 22,6% 7,2% 17,0% Medical 35,9% 17,3% Incontinence Products Custom Packs & Specialist Disposables A
Slide 6: Production – Main products
Production – Main products Farmex Medical Adult Incontinence Aids Custom Pack Standard Dressings Cotton Wool Advanced Dressings Surgical Suction Infusion and Systems Drainage Devices Svas Biosana Investor Presentation October 2026 6
Slide 7: Distribution – Main products
Distribution – Main products Specialties Cardiac Surgery Orthopedics and Arthroscopy Drug Transfer Devices for Peritoneal Dyalisis Cardiopulmonary TAVI Orthopedic Arthroscopy Implants Devices Anesthesia Products Implants and Equipment Radiology & Imaging Cardiology Laparoscopic Advanced Hemostatic C
Slide 8: Group Overview: 1H 2026 Sales Breakdown
Group Overview 1H 2026 Sales Breakdown By Activity By Geography By Customer Type Production Private 29% Customers 1H 2026 Foreign Sales1 ~ 23% 1H 2026 1H 2026 Countries Sales1 FY 2022 54% Sales1 Distribution 71% Italy 46% Public Customers ~ 77% First-class Suppliers National Public Hospitals Public
Slide 9: Investment Highlights and Market Dynamics
Group Overview Investment Highlights and Market Dynamics 1. Rich and consolidated portfolio of products to satisfy chronic, 2. Qualified commercial structure and close relationship with medical operators medical and surgical healthcare needs generate additional value while creating high entry barrie
Slide 10: Financial Data
Financial Data Key Financial Highlights Millions of Euro 20,00 € EBITDA 18,3 30,00% Millions of Euro Net Revenue 139,1 15,3 25,00% 140,00 € 120,3 14,2 118,3 15,00 € 120,00 € 11,9 20,00% Millions of Euro 2023A 2024A 2025A 1H 2025 1H2026 97,2 100,00 € 10,00 € 15,00% 80,00 € Net Revenue 118,3 120,3 139
Slide 11: Annex: Group Structure
Annex Group Structure Absolute majority of shares owned by Umberto Perillo Free Float and 21 Monte Umberto Svas Biosana Others Agrinvest S.r.l. Cofi Italia S.r.l. Belforte S.r.l. Board of Directors Somma S.r. 𝑙..(1) Perillo S.p.A. 43,86% 5,56% 6,93% 0,93% 8,19% 5,46% 29,08% Filippo Maraniello Chief
Slide 12: Annex: 1H Consolidated Income Statement
Annex 1H Consolidated Income Statement 30/06/2026 % 30/06/2025 % Delta % Revenues from sales and service 69.409.854 100,00% 70.424.155 100,00% -1.014.301 -1,44% External Costs 53.603.481 77,23% 54.376.434 77,21% -772.953 -1,42% Added Value 15.806.373 22,77% 16.047.721 22,79% -241.348 -1,50% Cost of
Slide 13: Annex: Consolidated Balance Sheet
Annex Consolidated Balance Sheet 30/06/2026 31/12/2025 Delta Net Intangible fixed assets 18.329.560 18.618.675 -289.115 Net Tangible Fixed Assets 27.658.169 27.679.991 -21.822 Equity investments and other financial fixed assets 68.553 68.553 0 Fixed Capital 46.056.282 46.367.219 -310.937 Inventory 4
Slide 14: Annex: Consolidated Income Statement
Annex Consolidated Income Statement 31.12.2025 % 31.12.2024 % Delta % Revenues from sales and service 139.112.593 100,0% 120.314.867 100,0% 18.797.726 15,6% External Costs 106.657.110 76,7% 92.562.304 76,9% 14.094.806 15,2% Added Value 32.455.483 23,3% 27.752.563 23,1% 4.702.920 16,9% Cost of labor
Slide 15: Annex: Consolidated Balance Sheet
Annex Consolidated Balance Sheet 31.12.2025 31.12.2024 Delta Net Intangible fixed assets 18.618.675 11.936.115 6.682.560 Net Tangible Fixed Assets 27.679.991 27.114.307 565.684 Equity investments and other financial fixed assets 68.553 110.179 (41.626) Fixed Capital 46.367.219 39.160.601 7.206.618 I
Slide 16: Legal Disclaimer
Legal Disclaimer Legal Disclaimer For the purposes of this disclaimer, this presentation (the “Presentation”) comprises the attached slides and any materials distributed at, or in connection with, the Presentation. The Presentation has been prepared bY Svas Biosana S.p.A. (the “Company”) solely for